Intensive care unit and emergency surgery medtech company CytoSorbents was awarded a nearly $2 million grant from the Defense Department to develop universal plasma.
The two-year research grant comes through funding from the Combat Casualty Care Research Program. The funding will be used to develop and test CytoSorbents HemoDefend-BGA product designed to remove anti-A and anti-B antibodies from plasma to create universal plasma, according to a Sept. 9 CytoSorbents news release.
"Our HemoDefend-BGA program has the potential to address a global need for universal plasma in both civilian and combat casualty care. This priority initiative continues to advance, benefitting from more than $11M in government contracts," CytoSorbents President and COO Vincent Capponi said. "Once the pre-clinical study and requisite benchtop testing are successfully completed, we plan to file a U.S. FDA pre-submission package to pursue human clinical trials with the goal of bringing this life-saving technology to the market."